Eur J Med Chem2023 Oct 05.
新規変異型EGFR阻害剤YK-029Aの発見:T790M変異とエクソン20挿入変異を標的とするNSCLCの治療薬
Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC.
Liu B, Gao F, Zhao H, Yuan S, Peng X, Zhang P, Wang J, Zhang T, Duan M, Guo Y